Full-Time
Updated on 9/9/2026
Medical device CDMO for cardiac devices
No salary listed
Palm Harbor, FL, USA
In Person
Occasional travel may be required.
Bachelor's, Master's
See people who can refer or advise you
Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
1940
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Adoption Assistance
Parental Leave
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]
Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.
Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.
KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.
Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.